The estimated Net Worth of Richard Brounstein is at least $288 millier dollars as of 10 February 2023. Mr Brounstein owns over 184 units of HeartBeam Inc stock worth over $252,243 and over the last 3 years he sold BEAT stock worth over $0. In addition, he makes $35,954 as Chief Financial Officer at HeartBeam Inc.
Mr has made over 13 trades of the HeartBeam Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 184 units of BEAT stock worth $414 on 10 February 2023.
The largest trade he's ever made was exercising 29,197 units of HeartBeam Inc stock on 11 November 2021 worth over $122,627. On average, Mr trades about 2,670 units every 29 days since 2021. As of 10 February 2023 he still owns at least 112,108 units of HeartBeam Inc stock.
You can see the complete history of Mr Brounstein stock trades at the bottom of the page.
Richard D. Brounstein is the Chief Financial Officer at HeartBeam Inc.
As the Chief Financial Officer of HeartBeam Inc, the total compensation of Mr Brounstein at HeartBeam Inc is $35,954. There are 14 executives at HeartBeam Inc getting paid more, with Joseph Capper having the highest compensation of $4,133,160.
Mr Brounstein is 71, he's been the Chief Financial Officer of HeartBeam Inc since . There are 1 older and 15 younger executives at HeartBeam Inc. The oldest executive at HeartBeam Inc is Robert Rubin, 74, who is the Independent Director.
Richard's mailing address filed with the SEC is 2118 WALSH AVE, SUITE 210, , SANTA CLARA, CA, 95050.
Over the last 11 years, insiders at HeartBeam Inc have traded over $23,124,978 worth of HeartBeam Inc stock and bought 31,500 units worth $221,145 . The most active insiders traders include Joseph H Capper, Heather C Getz et Willem Elfrink. On average, HeartBeam Inc executives and independent directors trade stock every 32 days with the average trade being worth of $55,046. The most recent stock trade was executed by Urioste George De on 6 September 2024, trading 1,674 units of BEAT stock currently worth $3,917.
heartbeam developed a mhealth technology that is diagnostically equivalent to a cardiologist reading a patient’s 12 lead ecg and examining the patient. it comprises a credit card size, 12 lead equivalent, ecg device and a cloud-based diagnostic expert system. studies designed by harvard medical school faculty have shown heartbeam performance to be equal or better than world class cardiologists in diagnosing a heart attack. the technology features personalized diagnostic thresholds and novel heart attack ecg markers from which the application can also help cardiologists locate a heart attack on a 3d model of the heart. heartbeam's icardiologist application utilizes artificial intelligence / machine learning to drive continuous improvements of the system's ability to provide patient analysis and improve the solution's predictive properties.
HeartBeam Inc executives and other stock owners filed with the SEC include: